The public offering price of $9 per share results in net proceeds to Seattle Genetics of approximately $97.5 million, after deducting underwriting discounts and commissions and offering expenses.
Seattle Genetics anticipates using the proceeds from this offering to fund R&D efforts, including clinical trials for its proprietary product candidates, and for general corporate purposes, including working capital.